See more : Grown Up Group Investment Holdings Limited (1842.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Organovo Holdings, Inc. (ONVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Organovo Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Valaris Limited WT (VAL-WT) Income Statement Analysis – Financial Results
- PCI Biotech Holding ASA (PCIB.OL) Income Statement Analysis – Financial Results
- MACOM Technology Solutions Holdings, Inc. (MTSI) Income Statement Analysis – Financial Results
- Matsuya R&D Co.,Ltd (7317.T) Income Statement Analysis – Financial Results
- Haw Par Corporation Limited (HAWPF) Income Statement Analysis – Financial Results
Organovo Holdings, Inc. (ONVO)
About Organovo Holdings, Inc.
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109.00K | 370.00K | 1.50M | 0.00 | 2.20M | 3.09M | 4.60M | 4.23M | 1.48M | 571.00K | 379.00K | 1.20M | 0.00 |
| Cost of Revenue | 0.00 | 293.00K | 142.00K | 41.00K | 328.00K | 482.00K | 1.03M | 956.00K | 18.01M | 12.92M | 7.97M | 4.34M | 0.00 |
| Gross Profit | 109.00K | 77.00K | 1.36M | -41.00K | 1.87M | 2.61M | 3.57M | 3.27M | -16.53M | -12.35M | -7.60M | -3.14M | 0.00 |
| Gross Profit Ratio | 100.00% | 20.81% | 90.53% | 0.00% | 85.06% | 84.41% | 77.62% | 77.40% | -1,114.30% | -2,162.87% | -2,003.96% | -262.32% | 0.00% |
| Research & Development | 5.50M | 8.89M | 3.32M | 1.10M | 5.28M | 14.75M | 17.96M | 19.55M | 18.01M | 12.92M | 7.97M | 3.44M | 0.00 |
| General & Administrative | 9.64M | 9.09M | 9.63M | 15.71M | 17.15M | 0.00 | 0.00 | 22.30M | 22.12M | 17.95M | 0.00 | 0.00 | 120.09K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.64M | 9.09M | 9.63M | 15.71M | 17.15M | 15.13M | 20.89M | 22.30M | 22.12M | 17.95M | 13.05M | 7.08M | 120.09K |
| Other Expenses | 0.00 | 128.00K | 28.00K | 15.00K | 909.00K | 0.00 | -12.00K | 0.00 | 0.00 | 0.00 | 0.00 | -9.00K | 120.09K |
| Operating Expenses | 15.20M | 18.10M | 12.98M | 16.83M | 23.34M | 29.88M | 38.84M | 41.85M | 40.13M | 30.87M | 21.03M | 10.52M | 120.09K |
| Cost & Expenses | 15.20M | 18.10M | 12.98M | 16.83M | 23.67M | 30.37M | 39.87M | 42.81M | 40.13M | 30.87M | 21.03M | 10.52M | 120.09K |
| Interest Income | 405.00K | 454.00K | 8.00K | 15.00K | 594.00K | 705.00K | 478.00K | 198.00K | 88.00K | 32.00K | 18.00K | 5.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 8.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 13.00K | 1.09M | 0.00 |
| Depreciation & Amortization | 280.00K | 293.00K | 142.00K | 41.00K | 1.14M | 983.00K | 1.27M | 1.15M | 815.00K | 472.00K | 387.00K | 195.00K | 2.28K |
| EBITDA | -14.81M | -17.44M | -11.34M | -16.78M | -20.33M | -26.29M | -34.00M | -37.43M | -37.83M | -29.61M | -25.45M | -26.00M | -1.12M |
| EBITDA Ratio | -13,583.49% | -4,718.38% | -755.80% | 0.00% | -954.96% | -848.63% | -738.82% | -880.09% | -2,544.84% | -5,217.69% | -5,341.42% | -940.52% | 0.00% |
| Operating Income | -15.09M | -17.73M | -11.48M | -16.83M | -21.48M | -27.27M | -35.27M | -38.58M | -38.64M | -30.30M | -20.65M | -9.32M | -147.82K |
| Operating Income Ratio | -13,840.37% | -4,792.16% | -765.27% | 0.00% | -977.91% | -882.37% | -766.26% | -911.94% | -2,605.73% | -5,305.95% | -5,448.28% | -778.53% | 0.00% |
| Total Other Income/Expenses | 417.00K | 474.00K | 33.00K | 2.00K | 2.77M | 642.00K | 470.00K | 151.00K | 71.00K | 215.00K | -5.20M | -34.23M | -1.19M |
| Income Before Tax | -14.67M | -17.26M | -11.45M | -16.82M | -18.71M | -26.63M | -34.80M | -38.42M | -38.57M | -30.08M | -25.85M | -43.55M | -147.82K |
| Income Before Tax Ratio | -13,457.80% | -4,664.05% | -763.07% | 0.00% | -851.91% | -861.60% | -756.05% | -908.37% | -2,600.94% | -5,268.30% | -6,820.05% | -3,638.51% | 0.00% |
| Income Tax Expense | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K | 3.00K | 2.00K | 23.00K | 3.00K | -215.00K | 5.20M | 34.23M | 27.72K |
| Net Income | -14.67M | -17.26M | -11.45M | -16.83M | -18.71M | -26.64M | -34.80M | -38.45M | -38.58M | -30.08M | -25.85M | -43.55M | -147.82K |
| Net Income Ratio | -13,459.63% | -4,664.59% | -763.20% | 0.00% | -852.00% | -861.70% | -756.09% | -908.91% | -2,601.15% | -5,268.30% | -6,820.05% | -3,638.51% | 0.00% |
| EPS | -1.60 | -1.98 | -1.32 | -2.44 | -2.89 | -4.62 | -6.49 | -7.87 | -8.57 | -7.55 | -7.07 | -13.03 | -0.04 |
| EPS Diluted | -1.60 | -1.98 | -1.32 | -2.44 | -2.89 | -4.62 | -6.49 | -7.87 | -8.35 | -7.55 | -7.07 | -20.19 | -0.04 |
| Weighted Avg Shares Out | 9.14M | 8.71M | 8.70M | 6.90M | 6.48M | 5.77M | 5.36M | 4.89M | 4.50M | 3.98M | 3.66M | 3.34M | 3.60M |
| Weighted Avg Shares Out (Dil) | 9.14M | 8.71M | 8.70M | 6.90M | 6.48M | 5.77M | 5.36M | 4.89M | 4.62M | 3.98M | 3.66M | 2.16M | 3.60M |
Catherine Wood's ARK Investment Slashes Organovo Holding
Catherine Wood ( Trades , Portfolio )'s ARK Investment Management has revealed a large reduction in the Organovo Holdings Inc. (NASDAQ:ONVO) position alongside a small reduction in the Syros Pharmaceuticals Inc. (NASDAQ:SYRS) position according to GuruFocus' Real-Time Picks, a Premium...
Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE)
SOLANA BEACH, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced it will be featured as a presenting company at the H.C. Wainwright Global Life Sciences Conference. The conference is being held on March 9-10, 2021...
ARKG: Potential Disruption For Healthcare And Pharma Industries
ARKG: Potential Disruption For Healthcare And Pharma Industries
ARKG: Don't Always Follow The Leader
Some of the best performing ETFs in recent years come from ARK Invest, which solely focuses on thematic disruptive tech. ARK Genomic Revolution was their best performer of 2020. ARK's CIO, Cathie Wood, is perhaps most famous for her $4,000...
3 Important Things I've Learned Reviewing ARK's ETFs
ARK Invest currently offers some of the best performing ETFs over the past five years. The five actively managed ETFs provided by ARK cover innovation, autonomous technology and robotics, next generation internet, genomics and fintech.
Wall Street Breakfast: The Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Organovo (NASDAQ:ONVO) vs. Gamida Cell (NASDAQ:GMDA) Head to Head Review
Organovo (NASDAQ:ONVO) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk. Volatility...
Reviewing Organovo (NASDAQ:ONVO) and AVITA MED LTD/S (NASDAQ:RCEL)
AVITA MED LTD/S (NASDAQ:RCEL) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation....
COVID-19 Impact on 3D Printing Medical Devices Market
Jun 01, 2020 (Heraldkeepers) -- New York, June 01, 2020: Market Research Engine has published a new report titled as "3D Printing Medical Devices Market Size...
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%
Source: https://incomestatements.info
Category: Stock Reports